FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer. METHODS: We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen (oxaliplatin [85 mg per square meter of body-surface area], irinotecan [180 mg per square meter, reduced to 150 mg per square meter after a protocol-specified safety analysis], leucovorin [400 mg per square meter], and fluorouracil [2400 mg per square meter] every 2 weeks) or gemcitabine (1000 mg per square meter on days 1, 8, and 15 every 4 weeks) for 24 weeks. The primary end point was disease-free survival. Secondary end points included overall survival and safety. RESULTS: At a median follow-up of 33.6 months, the median disease-free survival was 21.6 months in the modified-FOLFIRINOX group and 12.8 months in the gemcitabine group (stratified hazard ratio for cancer-related event, second cancer, or death, 0.58; 95% confidence interval [CI], 0.46 to 0.73; P<0.001). The disease-free survival rate at 3 years was 39.7% in the modified-FOLFIRINOX group and 21.4% in the gemcitabine group. The median overall survival was 54.4 months in the modified-FOLFIRINOX group and 35.0 months in the gemcitabine group (stratified hazard ratio for death, 0.64; 95% CI, 0.48 to 0.86; P=0.003). The overall survival rate at 3 years was 63.4% in the modified-FOLFIRINOX group and 48.6% in the gemcitabine group. Adverse events of grade 3 or 4 occurred in 75.9% of the patients in the modified-FOLFIRINOX group and in 52.9% of those in the gemcitabine group. One patient in the gemcitabine group died from toxic effects (interstitial pneumonitis). CONCLUSIONS: Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a higher incidence of toxic effects. (Funded by R&D Unicancer and others; ClinicalTrials.gov number, NCT01526135 ; EudraCT number, 2011-002026-52 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Polychemotherapy, either with 5-fluorouracil (5-FU), irinotecan and oxaliplatin in combination with folinic acid (FOLFIRINOX), or with gemcitabine and nab-paclitaxel (GnP), is considered the standard of care for patients suffering from metastatic PDAC (mPDAC)3,4.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [4]
In the citing paper
“Less than half of all patients respond to the primary treatment for PDAC, chemotherapy3,4”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Self-citationRahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,716
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,419
Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., Faluyi, O., O'Reilly, D. A., Cunningham, D., Wadsley, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32409-6 · Cited by 1,926
Self-citationOettle, H., Neuhaus, P., Hochhaus, A., Hartmann, J. T., Gellert, K., Ridwelski, K., Niedergethmann, M., Zülke, C., Fahlke, J., Arning, M. B., et al. (2013) · JAMA · doi:10.1001/jama.2013.279201 · Cited by 1,794
Research works printed but not linked: 1
- Early Breast Cancer Trialists’ Collaborative Group. Treatment of early breast cancer. Vol. 1. Worldwide evidence 1985–1990. Oxford England: Oxford University Press 1990.
Cited by
Items 901–1,000 of 1,002
Wo, J. Y.-L., Clark, J. W., Eyler, C. E., Mino-Kenudson, M. A., Klempner, S. J., Allen, J. N., Keane, F. K., Parikh, A. R., Roeland, E. J., Drapek, L. C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0331 · Cited by 16
Rieser, C. J., Zenati, M. S., Narayanan, S., Bahary, N., Lee, K. K. W., Paniccia, A., Bartlett, D. L., & Zureikat, A. H. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-09822-1 · Cited by 20
Fan, Y., Li, Z., Wu, L., Lin, F., Shao, J., Ma, X., Yao, Y., Zhuang, W., & Wang, Y. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s266746 · Cited by 16
RetractedCleary, J. M., Wolpin, B. M., Dougan, S. K., Raghavan, S., Singh, H., Huffman, B. M., Sethi, N. S., Nowak, J. A., Shapiro, G. I., Aguirre, A. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1367 · Cited by 18
Iyengar, S. K., Nevala-Plagemann, C., & Garrido‐Laguna, I. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211045861 · Cited by 17
Pekarek, L., Fraile‐Μartinez, O., Montero, C. G., Álvarez-Mon, M. Á., Acero, J., Ruiz‑Llorente, L., García‐Honduvilla, N., Albillos, A., Buján, J., Álvarez‐Mon, M., et al. (2021) · Oncology Letters · doi:10.3892/ol.2021.13070 · Cited by 17
Park, T. H., & KIM, H. S. (2021) · Anticancer Research · doi:10.21873/anticanres.15506 · Cited by 17
Yan, J., Yuan, P., Gui, L., Wang, Z., Yin, P., Gao, W., & Ma, B. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211068958 · Cited by 17
Treatment of pancreatic cancer in 2022
Casolino, R., & Biankin, A. V. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.2 · Cited by 17
Impact of Immunotherapy after Resection of Pancreatic Cancer
Tran, T. B., Maker, V. K., & Maker, A. V. (2019) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2019.01.016 · Cited by 16
Holub, K., & Conill, C. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02113-y · Cited by 16
Cherkassky, L., & Jarnagin, W. R. (2019) · Updates in Surgery · doi:10.1007/s13304-019-00670-z · Cited by 15
Greco, S. H., August, D. A., Shah, M. M., Chen, C., Moore, D. F., Masanam, M. K., Turner, A. L., Jabbour, S. K., Javidian, P., Grandhi, M. S., et al. (2020) · Surgery Open Science · doi:10.1016/j.sopen.2020.12.001 · Cited by 15
“Post-operative systemic chemotherapy has been shown to be effective in randomized clinical trials [2].”
BackgroundGlycemic Control as an Early Prognostic Marker in Advanced Pancreatic Cancer
Alpertunga, I., Sadiq, R., Pandya, D. S., Lo, T., Dulgher, M., Evans, S., Bennett, B., Rennert, N. J., & Frank, R. C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.571855 · Cited by 17
“Impaired glucose tolerance is present in most patients diagnosed with PDAC and between 25%–50% have pre-existing DM, the majority classified as new-onset (1, 2).”
BackgroundAriake, K., Mizuma, M., Motoi, F., Maeda, S., Morikawa, T., Ishida, M., Ohtsuka, H., Aoki, S., Miura, T., Takadate, T., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-09718-0 · Cited by 15
Para-aortic lymph nodes and ductal adenocarcinoma of the pancreas: Distant neighbors?
Safi, S. A., Rehders, A., Häberle, L., Fung, S., Lehwald, N., Esposito, I., Ziayee, F., Krieg, A. H., Knoefel, W. T., & Fluegen, G. (2021) · Surgery · doi:10.1016/j.surg.2021.06.045 · Cited by 15
FOLFIRINOX Adjuvant Therapy for Pancreatic Cancer
Vivaldi, C., Fornaro, L., & Vasile, E. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1900712 · Cited by 15
Metabolic reprogramming of drug resistance in pancreatic cancer: mechanisms and effects
Zhang, J., Kong, X., Zhou, B., Li, R., Yu, Z., Zhu, J., Xi, Q., Li, Y., Zhao, Z., & Zhang, R. (2025) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2025.101368 · Cited by 16
Raphael, M. J., Raskin, W., Habbous, S., Tai, X., Beca, J. M., Dai, W. F., Arias, J., Forbes, L. M., Gavura, S., Biagi, J. J., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.33388 · Cited by 14
Self-citationAmorim, L. C., & Peixoto, R. D. (2021) · International Cancer Conference Journal · doi:10.1007/s13691-021-00526-7 · Cited by 18
“without 5-FU bolus and dose-reduced irinotecan (150 mg/ m2) has become the most active regimen to decrease recurrence and increase survival following pancreatic adenocarcinoma resection [32].”
BackgroundEttrich, T. J., Sturm, N., Güthle, M., Hüttner, F. J., & Perkhofer, L. (2022) · Visceral Medicine · doi:10.1159/000521631 · Cited by 15
Spek, C. A., Aberson, H. L., & Duitman, J. (2022) · Biomedicines · doi:10.3390/biomedicines10020219 · Cited by 15
“Chemotherapy-based therapies therefore remain standard of care [5], but chemotherapeutic treatments only minimally affect PDAC progression [6,7], therefore improving the efficacy of chemotherapy in PDAC is of utmost importance.”
BackgroundProton Therapy in the Management of Pancreatic Cancer
Kobeissi, J. M., Simone, C. B., Lin, H., Hilal, L., & Hajj, C. (2022) · Cancers · doi:10.3390/cancers14112789 · Cited by 15
“After surgical resection, the standard of care is to offer adjuvant chemotherapy [10], with conflicting evidence on the role of adjuvant radiation therapy [11,12].”
BackgroundOkada, K., Kouda, K., Kawai, M., Hirono, S., Miyazawa, M., Kitahata, Y., Kawanishi, M., Natsume, Y., Wan, K., & Yamaue, H. (2022) · Journal of the American College of Surgeons · doi:10.1097/xcs.0000000000000408 · Cited by 15
Miotke, L. K., Nevala-Plagemann, C., Ying, J., Florou, V., Haaland, B. A., & Garrido‐Laguna, I. (2022) · BMC Cancer · doi:10.1186/s12885-022-10130-4 · Cited by 14
“Similarly, in the ESPAC-4 and PRODIGE-24 trials, which demonstrated superiority of multiagent cytotoxic regimens over adjuvant gemcitabine alone, the recurrence rates were 65% and 51%, respectively [5, 6].”
ResultStern, L., Boehme, L. F., Goetz, M. R., Nitschke, C., Giannou, A. D., Zhang, T., Güngör, C., Reeh, M., Izbicki, J. R., Fliegert, R., et al. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5454 · Cited by 14
“FOLFIRINOX was first introduced to clinical practice in 2010 and has since rapidly emerged as the standard treatment option for patients with PDAC due to its superior response rates compared with previously established chemotherapeutic regimens (6,49).”
BackgroundResultde Almeida, D. R. Q., dos Santos, A. F., Wailemann, R. A. M., Terra, L. F., Gomes, V. M., Arini, G. S., Bertoldi, E. R. M., Reis, E. M. R., Baptista, M. S., & Labriola, L. (2022) · Photochemical & Photobiological Sciences · doi:10.1007/s43630-022-00347-4 · Cited by 15
“The increase in necroptosis markers observed in samples from FOLFIRINOX treated patients was associated to a better outcome when compared with other chemotherapies, highlighting the potential improvements in PDAC treatment that can be explored by activating alternative regulated cell death mechanisms [34, 54].”
BackgroundResultRegulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies
Wang, Z., Wu, B., Nie, G., Wei, J., & Li, Y. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216138 · Cited by 18
Park, B. K., Seo, J. H., Han, J., Lee, K. J., Son, K. J., & Choi, J. K. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.05.020 · Cited by 14
Kwaśniewska, D., Fudalej, M. M., Nurzyński, P., Badowska-Kozakiewicz, A. M., Czerw, A. I., Cipora, E., Sygit, K., Bandurska, E., & Deptała, A. (2023) · Cancers · doi:10.3390/cancers15174275 · Cited by 16
“003) and established the standard in adjuvant management [26,27] in R-PDAC.”
BackgroundWitz, A., Dardare, J., François, A., Husson, M., Rouyer, M., Demange, J., Merlin, J., Gilson, P., & Harlé, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-45964-w · Cited by 20
Turner, K. M., Wilson, G. C., Patel, S. H., & Ahmad, S. A. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-14585-y · Cited by 24
“11 Multimodal therapy can be thought of as locoregional therapy, including surgical resection and radiation, and systemic therapy, including chemotherapy.”
Paiella, S., Malleo, G., Lionetto, G., Cattelani, A., Casciani, F., Secchettin, E., Pastena, M. D., Bassi, C., & Salvia, R. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-14951-4 · Cited by 14
“5 Finally, AT access is considered a quality metric in pancreas surgery to evaluate systems performance at institutional levels.”
BackgroundGenetically engineered membrane-based nanoengagers for immunotherapy of pancreatic cancer
Zhang, H., Li, Y., Kang, H., Lan, J., Hou, L., Chen, Z., Li, F., Liu, Y., Zhao, J., Li, N., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02369-9 · Cited by 17
“Although surgical intervention combined with chemotherapy, such as gemcitabine and FOLFIRINOX, has shown incremental improvements in survival for pancreatic cancer [4], the majority of patients are diagnosed at an advanced stage, rendering them ineligible for surgery [5–7].”
BackgroundTasu, J., Herpe, G., Damion, J., Richer, J.-P., Debeane, B., Vionnet, M., Rouleau, L., Carretier, M., Ferru, A., Ingrand, P., et al. (2024) · European Radiology · doi:10.1007/s00330-024-10613-x · Cited by 14
“For patients with resection R0/R1, mean overall survival rate is 70% at 18 months [23].”
Wang, Q., Wang, J., Xu, K., & Luo, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1481247 · Cited by 21
Jia, Q.-Y., Zhu, Y., Yao, H., Yin, Y., Duan, Z., Zheng, J.-H., Ma, D., Yang, M., Yang, J., Zhang, J., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07110-w · Cited by 22
“The fi ndings that modi fi ed FOLFIRINOX versus gemcitabine adjuvant chemotherapy after resection of pancreatic cancer, as reported by ASCO in 2018 [5], have further extended this three-agent combination chemotherapy regimen to post-operative adjuvant chemotherapy.”
BackgroundMaulat, C., Canivet, C., Cabarrou, B., Pradines, A., Sèlves, J., Casanova, A., Doussine, A., Hanoun, N., Cuellar, E., Boulard, P., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-76903-y · Cited by 18
Iglesias-Matesanz, P., Lacalle-González, C., Lopez-Blazquez, C., Otieno, M. O., García‐Foncillas, J., & Martínez‐Useros, J. (2024) · Antioxidants · doi:10.3390/antiox13111405 · Cited by 21
“FOLFIRINOX, a multi-drug regimen composed of folinic acid, 5-FU, irinotecan, and oxaliplatin, offered a better OS of 21.6 months compared to 12.8 months with gemcitabine [5].”
InfluentialCase Report of Exercise to Attenuate Side Effects of Treatment for Pancreatic Cancer
Mclaughlin, M., Christie, A., & Campbell, A. (2019) · Case Reports in Oncology · doi:10.1159/000503815 · Cited by 16
Weniger, M., Miksch, R. C., Maisonneuve, P., Werner, J., & D’Haese, J. G. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.02.016 · Cited by 14
Collard, M. K., Voron, T., Svrcek, M., Ahmed, O., Balladur, P., Hor, T., André, T., & Paye, F. (2020) · HPB · doi:10.1016/j.hpb.2020.02.009 · Cited by 14
Amin, S., Baine, M. J., Meza, J. L., & Lin, C. H. (2020) · BMC Cancer · doi:10.1186/s12885-020-07016-8 · Cited by 13
Miccio, J. A., Talcott, W. J., Patel, T. H., Park, H. S.-M., Cecchini, M., Salem, R. R., Khan, S. A., Stein, S., Kortmansky, J. S., Lacy, J., et al. (2020) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2020.12.003 · Cited by 14
“[7,8]; however, the addition of RT further improves the R0 resection rate and pathologic down-staging compared to MAC alone [14,16,17].”
BackgroundResultKhachfe, H. H., Chahrour, M. A., Habib, J. R., Yu, J., & Jamali, F. R. (2021) · World Journal of Surgery · doi:10.1007/s00268-021-05989-6 · Cited by 13
Future directions in drug development in pancreatic cancer
Lambert, A., Conroy, T., & Ducreux, M. P. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.002 · Cited by 15
Self-citationWhich patients benefit from preoperative biliary drainage in resectable pancreatic cancer?
Blacker, S., Lahiri, R. P., Phillips, M., Pinn, G., Pencavel, T. D., Kumar, R., Riga, A. T., Worthington, T. R., Karanjia, N. D., & Frampton, A. E. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1915127 · Cited by 14
“FOLFIRINOX are imitated by the use of the same agents in the adjuvant setting, suggesting that the agent of choice has more impact than the timing of therapy [32,33,35].”
BackgroundComprehensive molecular profiling to predict clinical outcomes in pancreatic cancer
Hong, J. Y., Cho, H. J., Kim, S. T., Park, Y. S., Shin, S. H., Han, I. W., Lee, J., Heo, J. S., & Park, J. O. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211038478 · Cited by 15
Joliat, G., Labgaa, I., Sulzer, J., Vrochides, D. V., Zerbi, A., Nappo, G., Périnel, J., Adham, M., van Roessel, S. R., Besselink, M. G., et al. (2021) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-21-99 · Cited by 14
“Nevertheless, improved 3-year survival up to 63% has recently been reported by combining complete surgical resection and potent adjuvant chemotherapy (6).”
Additional MRI for initial M-staging in pancreatic cancer: a cost-effectiveness analysis
Gassert, F. G., Ziegelmayer, S., Luitjens, J., Gassert, F. T., Tollens, F., Rink, J., Makowski, M. R., Rübenthaler, J., & Froelich, M. F. (2021) · European Radiology · doi:10.1007/s00330-021-08356-0 · Cited by 14
“In particular, FOLFIRINOX was shown to significantly prolong survival, however, at the expense of increased toxicity [6, 7].”
BackgroundAccurate Nodal Staging in Pancreatic Cancer in the Era of Neoadjuvant Therapy
Javed, A. A., Ding, D., Baig, E., Wright, M. J., Teinor, J. A., Ali, D. M., Thompson, E. D., Hruban, R. H., Narang, A. K., Burns, W. R., et al. (2022) · World Journal of Surgery · doi:10.1007/s00268-021-06410-y · Cited by 15
Zebrafish Xenograft Model for Studying Pancreatic Cancer-Instructed Innate Immune Microenvironment
Wang, X., Li, W., Jiang, H., Ma, C., Huang, M., Wei, X., Wang, W., & Jing, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126442 · Cited by 16
“Improved strategies such as FOLFIRINOX combined chemotherapy have provided certain amounts of effects, but still show low responses and patients develop resistance quickly [3].”
BackgroundLin, Q., Shen, S., Qian, Z., Rasam, S. S., Serratore, A., Jusko, W. J., Kandel, E., Qu, J., & Straubinger, R. M. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100409 · Cited by 14
Kaslow, S. R., Sacks, G. D., Berman, R. S., Lee, A. Y., & Correa‐Gallego, C. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005753 · Cited by 14
Choi, M., Wang, S., Park, J. S., Kim, H. S., Choi, S. H., Lee, J. H., Chong, J. U., Nagakawa, Y., Wada, K., Nakamura, Y., et al. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000537 · Cited by 14
“AT has been shown to be bene fi cial in prolonging survival for PDAC [12] .”
BackgroundCloyd, J. M., Tsung, A., Hays, J. L., Wills, C. E., & Bridges, J. F. P. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i4.375 · Cited by 14
Neyaz, A., Tabb, E. S., Shih, A. R., Zhao, Q., Shroff, S. G., Taylor, M. S., Rickelt, S., Wo, J. Y.-L., Castillo, C. F. F.-D., Qadan, M., et al. (2020) · Histopathology · doi:10.1111/his.14086 · Cited by 14
Sahai, A. V., Arya, N., Wyse, J., Jayaraman, S., Ball, C., Lam, E., Paquin, S. C., & Lightfoot, P. (2020) · Endoscopic Ultrasound · doi:10.4103/eus.eus_28_20 · Cited by 14
“This strategy has been bolstered by recent randomized controlled trials demonstrating longer overall survival improvements with median overall survival in excess of 4 years in prospective studies.[55,56] The challenge with chemotherapy following surgery is that between 40% and 60% of patients never receive chemotherap…”
MethodSham, J. G., Guo, S., Ding, D., Shao, Z., Wright, M. J., Jing, W., Yin, L.-D., Zhang, Y., Gage, M. M., Zhou, Y., et al. (2020) · Chinese Clinical Oncology · doi:10.21037/cco-20-6 · Cited by 14
Factors Influencing Exercise Following Pancreatic Tumor Resection
Parker, N. H., Basen‐Engquist, K., Rubin, M., Li, Y., Prakash, L., Ngo‐Huang, A., Gorzelitz, J., Ikoma, N., Lee, J. E., & Katz, M. H. G. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09062-9 · Cited by 14
Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities
Wang, Y., Lakoma, A., & Zogopoulos, G. (2020) · Genes · doi:10.3390/genes11091098 · Cited by 16
Microscopic resection margin status in pancreatic ductal adenocarcinoma – A nationwide analysis
Daamen, L. A., van Goor, I. W. J. M., Schouten, T. J., Dorland, G. A., van Roessel, S. R., Besselink, M. G., Bonsing, B. A., Bosscha, K. P., Brosens, L. A. A., Busch, O. R., et al. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.11.145 · Cited by 14
Hüttner, F. J., Klotz, R., Giese, N. A., Kong, B., Ahmed, A., Merz, D., Pöchmann, A., Burghaus, I., Hackert, T., Strobel, O., et al. (2025) · Langenbeck's Archives of Surgery · doi:10.1007/s00423-025-03735-3 · Cited by 15
Ecker, B. L., Court, C. M., Janssen, Q. P., Tao, A. J., D’Angelica, M. I., Drebin, J. A., Gonen, M., O’Reilly, E. M., Jarnagin, W. R., Wei, A. C., et al. (2022) · Journal of the American College of Surgeons · doi:10.1097/xcs.0000000000000212 · Cited by 13
Self-citationHüttner, F. J., Rooman, I., Bouche, G., Knebel, P., Hüsing, J., Mihaljevic, A. L., Hackert, T., Strobel, O., Büchler, M. W., & Diener, M. K. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-040406 · Cited by 13
Gehrels, A. M., Vissers, P. A. J., Sprangers, M. A. G., Fijnheer, N. M., Pijnappel, E. N., van der Geest, L. G., Cirkel, G. A., de Vos‐Geelen, J., Homs, M. Y. V., Creemers, G. J., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.103068 · Cited by 13
“31,32 This was observed in both the C-PAC and M1-C-PAC group, where complaints of diarrhea and side effects increased clinically relevantly during treatment, potentially attributable to the effects of chemotherapy.”
Glapiński, F., Zając, W., Fudalej, M. M., Deptała, A., Czerw, A. I., Sygit, K., Kozłowski, R., & Badowska-Kozakiewicz, A. M. (2025) · Cancers · doi:10.3390/cancers17101599 · Cited by 16
“[8].”
Belfiori, G., Stefano, F. D., Tamburrino, D., Gasparini, G., Aleotti, F., Camisa, P. R., Arcangeli, C., Lena, M. S., Pecorelli, N., Palumbo, D., et al. (2025) · BJS Open · doi:10.1093/bjsopen/zraf033 · Cited by 16
“In the setting of localized and resectable (R) disease amenable to immediate surgery, 20–30% of patients will be alive after 5 years 3–10 , with only around 11% being disease-free 11,12 .”
Responsive nanomedicine strategies achieve pancreatic cancer precise theranostics
Li, F., Tang, Z., Zheng, Y., Jiang, T., Deng, L., Dai, W., Zhao, Y., Zheng, N., Liu, S., Fan, Y., et al. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.08.012 · Cited by 36
“Patients with preserved functional status should receive modified FOLFIRINOX (5-fluorouracil, oxaliplatin, irinotecan, leucovorin), while gemcitabine-based regimens (with/without capecitabine) are indicated for those with compromised status [41 – 43].”
Roth, S., Apte, M. V., Balachandran, V. P., Biffi, G., Conroy, T., Cukierman, E., Dotan, E., Esposito, I., Grünwald, B. T., Klauß, M., et al. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00699-6 · Cited by 28
Self-citationGeerdes, E. E., Sideras, K., Aziz, M. H., van Eijck, C. H. J., Bruno, M. J., Sprengers, D., Boor, P. P. C., & Kwekkeboom, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.615691 · Cited by 14
“html) and that is despite improvements in modern adjuvant chemotherapeutic treatments for early pancreatic cancer (6).”
BackgroundReddy, A. V., Hill, C., Sehgal, S., He, J. P., Zheng, L., Herman, J. M., Meyer, J. J., & Narang, A. K. (2022) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-22-38 · Cited by 11
Kim, H. S., Lee, M., Han, Y., Kang, J. S., Kang, Y. H., Sohn, H. J., Kwon, W., Lee, D. H., & Jang, J. (2023) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.1302 · Cited by 13
Technical options in surgery for artery-involving pancreatic cancer: Invasion depth matters
Miao, Y., Cai, B., & Lu, Z. (2023) · Surgery Open Science · doi:10.1016/j.sopen.2023.03.001 · Cited by 13
“Radical surgery has long been the only chance of curing pancreatic cancer, and provides a 5-year survival rate of 30–50 % if combined with modern adjuvant chemotherapy [3,4].”
BackgroundSharma, A., Bomzan, P., Roy, N., Dakua, V. K., Roy, K., Barman, A., Dey, R., Chhetri, A., Dewan, R., Dutta, A., et al. (2023) · ACS Omega · doi:10.1021/acsomega.3c02783 · Cited by 14
Selection of patients with pancreatic adenocarcinoma who may benefit from radiotherapy
Jan, I., & Ch’ang, H.-J. (2023) · Radiation Oncology · doi:10.1186/s13014-023-02328-y · Cited by 16
“radical surgery and intensive systemic chemotherapy [9, 10, 27].”
BackgroundThe diagnosis and treatment of ampullary carcinoma
Walter, D. H., Schnitzbauer, A. A., Schulze, F., & Trojan, J. (2023) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2023.0195 · Cited by 13
Personalized treatment in localized pancreatic cancer
Neoptolemos, J. P., Hu, K., Bailey, P. J., Springfeld, C., Cai, B., Miao, Y., Michalski, C. W., Carvalho, C. T., Hackert, T., & Büchler, M. W. (2023) · European surgery. Supplement/European surgery · doi:10.1007/s10353-023-00814-x · Cited by 16
“The integration of adjuvant multiagent chemotherapy after primary resection has significantly improved prognosis from 10% or less with surgery± chemoradiotherapy to 30–50% with combination regimens, depending on patient selection [8–13].”
Zhang, C., Li-hong, J., Zhou, X., He, Y.-P., Liu, Y., Zhou, D., Lv, Y., Wu, B., & Zhao, Z. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101812 · Cited by 17
“Of the PARP inhibitors, Olaparib has been approved by the U.S. Food and Drug Administration (FDA) for BRCA-mutated metastatic PDAC treatment [10,14].”
BackgroundInfluentialWillems, R. A. L., Biesmans, C., Campello, E., Simioni, P., de Laat, B., de Vos‐Geelen, J., Roest, M., & Cate, H. T. (2023) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0043-1777304 · Cited by 17
Yuen, J. G., Hwang, G., Fesler, A. T., Intriago, E., Pal, A. S., Ojha, A., & Ju, J. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200769 · Cited by 18
“5 8 However, these regimens are still largely ineffective, as the median overall survival is only marginally improved relative to monotherapy, and the overall survival has not dramatically improved in the past 30 years.”
BackgroundEffect of surgery versus chemotherapy in pancreatic cancer patients: a target trial emulation
Kirkegård, J., Gaber, C. E., Heide‐Jørgensen, U., Fristrup, C. W., Lund, J. L., Cronin-Fenton, D. P., & Mortensen, F. V. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae024 · Cited by 17
Huan, L., Yu, F., Cao, D., Zhou, H., Qin, M., & Cao, Y. (2024) · PLoS ONE · doi:10.1371/journal.pone.0295983 · Cited by 16
Akita, H., Mukai, Y., Kubo, M., Takahashi, H., Hasegawa, S., Kitakaze, M., Matsuura, N., Masuike, Y., Sugase, T., Shinno, N., et al. (2024) · Surgery · doi:10.1016/j.surg.2024.06.049 · Cited by 13
Treekitkarnmongkol, W., Dai, J., Liu, S., Sankaran, D., Nguyen, T., Balasenthil, S., Hurd, M. W., Chen, M., Katayama, H., Roy‐Chowdhuri, S., et al. (2024) · Gastro Hep Advances · doi:10.1016/j.gastha.2024.08.002 · Cited by 16
FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer
Stein, L., Murugesan, K., Reeser, J. W., Risch, Z. A., Wing, M. R., Paruchuri, A., Samorodnitsky, E., Hoskins, E. L., Dao, T., Smith, A. M., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00683-x · Cited by 16
“…on this trial, genomic testing revealed an FGFR2-USP33 fusion, and she subsequently started a basket trial for the FGFR-selectiveinhibitorpemigatinibwheresheexhibitedapartialresponse witha43%reductionintumorsize(NCT02393248)andremainedon therapyfor28months(Fig.1A,SupplementaryFigs.1,2B,4) 8 .”
BackgroundTumor organoids improve mutation detection of pancreatic ductal adenocarcinoma
Farshadi, E. A., Wang, W., Mohammad, F., van der Oost, E., Doukas, M., van Eijck, C. H. J., van de Werken, H. J. G., & Katsikis, P. D. (2024) · Scientific Reports · doi:10.1038/s41598-024-75888-y · Cited by 16
“%) with no driver mutations detected in either the tumors or the organoids. tumors 44,45 .”
BackgroundKocher, H. M., BCI-STARPAC2 team, Ackerman, C., Priyadarshini, G., Lawrence, C. A. C., Kotriwala, N., Georgescu, R., BPTB team, Roberts, R., Hughes, C., et al. (2025) · BMC Cancer · doi:10.1186/s12885-024-13333-z · Cited by 15
da Costa, W. L., Cao, H. S. T., Sheetz, K. H., Gu, X., Norton, E. C., & Massarweh, N. N. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09327-3 · Cited by 13
Immunomodulation in Pancreatic Cancer
Krishnamoorthy, M., Lenehan, J. G., Burton, J. P., & Vareki, S. M. (2020) · Cancers · doi:10.3390/cancers12113340 · Cited by 15
“4 months when combined with adjuvant FOLFIRINOX [8].”
BackgroundInfluentialOkada, Y., Nishiwada, S., Yamamura, K., Sho, M., Baba, H., Takayama, T., & Goel, A. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2020.12.031 · Cited by 13
Elshami, M., Hue, J. J., Hoehn, R. S., Rothermel, L. D., Bajor, D. L., Mohamed, A., Selfridge, J. E., Chavin, K. D., Ammori, J. B., Hardacre, J. M., et al. (2022) · HPB · doi:10.1016/j.hpb.2021.12.022 · Cited by 13
Hughes, D. L., Hughes, I., & Silva, M. A. (2022) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2022.01.028 · Cited by 15
Li, D., Wang, L., Cai, W., Liang, M., Ma, X., & Zhao, X. (2022) · European Journal of Radiology · doi:10.1016/j.ejrad.2022.110313 · Cited by 15
Importance of triple tumor markers as biomarkers in patients with pancreatic ductal adenocarcinoma
Takagi, T., Nagai, M., Nishiwada, S., Terai, T., Yasuda, S., Matsuo, Y., Doi, S., Kohara, Y., & Sho, M. (2022) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12629 · Cited by 13
van Eijck, C. W. F., de Koning, W., van der Sijde, F., Moskie, M., Koerkamp, B. G., Homs, M. Y. V., van der Burg, S. H., van Eijck, C. H. J., & Mustafa, D. A. M. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.12.024 · Cited by 15
Harnessing the Microbiome to Reduce Pancreatic Cancer Burden
Bastos, A. R., Pereira‐Marques, J., Ferreira, R. M., & Figueiredo, C. (2023) · Cancers · doi:10.3390/cancers15092629 · Cited by 15
“Another chemotherapeutic option for treating advanced PDAC is the FOLFIRINOX regimen (5-FU, leucovorin, irinotecan, and oxaliplatin) [82].”
BackgroundAdjuvant and neoadjuvant approaches in pancreatic cancer
Conroy, T., Lambert, A., & Ducreux, M. P. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000962 · Cited by 14
“The PRODIGE-24-CCTG PA6 French-Canadian trial randomized 493 patients aged less than 80years to receive adjuvant mFOLFIRINOX or gemcitabine [4].”
MethodSelf-citationNapoli, N., Kauffmann, E. F., Menonna, F., Iacopi, S., Cacace, C., & Boggi, U. (2020) · Journal of Visualized Experiments · doi:10.3791/60370 · Cited by 13
Itchins, M., Chua, T. C., Arena, J., Jamieson, N. B., Nahm, C. B., O’Connell, R. L., Bailey, E. A., Schembri, G. P., Gill, A. J., Kneebone, A. B., et al. (2020) · Pancreas · doi:10.1097/mpa.0000000000001472 · Cited by 13
Metadata
- Authors
- Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., Lecomte, T., Assenat, E., Faroux, R., Ychou, M., Volet, J., Sauvanet, A., Breysacher, G., Di Fiore, F., Cripps, C., Kavan, P., Texereau, P., Bouhier-Leporrier, K., Khemissa-Akouz, F., Legoux, J.-L., Juzyna, B., Gourgou, S., O’Callaghan, C. J., Jouffroy-Zeller, C., Rat, P., Malka, D., Castan, F., & Bachet, J.-B.
- Affiliations
- Hôpital Beaujon (FR)
- From the Institut de Cancérologie de Lorraine and Université de Lorraine (T.C.) and Centre Hospitalier Universitaire (L.C.), Nancy, Hôpital Beaujon and University Paris VII, Clichy (P.H., A.S.), Hôpital Huriez, Lille (M.H.), Centre Paul Strauss, Strasbourg (M.B.A.), Institut Paoli-Calmettes, Marseille (J.-L.R.), Centre Antoine-Lacassagne, Nice (E.F.), Hôpital Jean-Mermoz, Lyon (P.A.), Hôpital Trousseau, Tours (T.L.), Centre Hospitalier Universitaire de Saint-Eloi (E.A.) and Institut du Cancer de...
- Université de Montpellier (FR)
- Université Paris-Saclay (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-12-20
- Volume
- 379
- Issue
- 25
- Pages
- 2395-2406
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2903623792
- Cited by
- 2,874
- References
- 22
- Citations by year
- 2026: 219 · 2025: 316 · 2024: 337 · 2023: 457 · 2022: 449 · 2021: 512 · 2020: 376 · 2019: 202 · 2018: 1
- FWCI
- 102.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Canadian Cancer Society (Program Grant #704970)
- Institut National du Cancer (Clinical Research Hospital Program grant (PHRC11-0)
- 7 Days in May
- French National League against Cancer
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- FOLFIRINOX, gemcitabine, adjuvant chemotherapy, pancreatic ductal adenocarcinoma, resected pancreatic cancer, disease-free survival, overall survival, oxaliplatin, irinotecan, 5-fluorouracil, leucovorin, adverse events, treatment safety, secondary malignancies, metastatic pancreatic cancer, combination chemotherapy
- MeSH terms
- Irinotecan, Oxaliplatin, Gemcitabine, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Deoxycytidine, Drug Combinations, Female, Fluorouracil, Humans, Male, Middle Aged, Organometallic Compounds, Pancreatic Neoplasms, Prospective Studies, Proportional Hazards Models, Chemotherapy, Adjuvant, Lung Diseases, Interstitial, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.